Haiti Videos > Opinions > VIDEO A Haitian Funeral...

Ron Research was committed to ensuring that its return to...

Youngtoussaint Says...

ron Research was committed to ensuring that its return to short selling was marked by a report
that would not only hinge on valuation concerns but also spotlight a company whose activities
could be detrimental to the public interest.

We held ourselves to the highest standard, making
sure the information we disclosed would be irrefutable, lucid, and would empower the
appropriate regulators to take necessary actions.

With that we present Apellis Pharmaceuticals
Background (Readers Digest Version)
"In 2023, Apellis Pharmaceuticals released Syfovre, marking it as the first FDA-approved
treatment for Geographic Atrophy.

Remarkably, the drug attained approval without the
convening of an FDA advisory committee, a decision that has sparked considerable debate since
its launch.

To connect with an aging demographic, Apellis brought on the The Fonz as the face
of its marketing campaign.

This move proved effective, leading to widespread early adoption,
and a buzz of excitement on Wall Street regarding the drug's potential

Posted November 29 2023 at 8:31 PM

REPLY to this message

or start a NEW Topic

  Topic »

Messages in Topic

Subject Author Date
Depi Moun Sa Yo La Prepapre Cerceuil Pou. H On Brazilian Companies By Teso And Coauthors Emanuele Colonnelli Of The University... Toussaintfreedom 11/24/2023
Ron Research Was Committed To Ensuring That Its Return To Short Selling Was Marked By A Report That Would Not Only Hinge On... Youngtoussaint 11/29/2023